Management of Neuropathic Pain in Crohn's Disease

Introduction to Pain Management

The European Crohn's and Colitis Organisation recommends that pain experienced by Crohn's patients requires careful phenotyping before considering pregabalin, including distinguishing between inflammatory, non-inflammatory, and neuropathic pain 1, 2
The American Gastroenterological Association suggests that 50-70% of Crohn's patients experience pain during disease flares, and pain can persist even without evidence of active inflammation on investigation 1, 2

Pregabalin should only be considered after establishing that pain has neuropathic characteristics and that IBD therapy has been optimized, according to the American College of Gastroenterology 1, 2
The European Society for Clinical Nutrition and Metabolism indicates that pain persisting despite adequate control of inflammatory disease activity is a specific indication for pregabalin 1, 2

The American Academy of Neurology recommends starting with a low dose of pregabalin (75 mg at bedtime) and titrating slowly to minimize side effects while maximizing tolerability 1, 2

The American Pain Society suggests that combination neuropathic analgesics, such as pregabalin and duloxetine, may be more effective than monotherapy for severe refractory pain 5, 6
The European Federation of Neurological Societies recommends monitoring for serotonin syndrome when combining medications, especially SSRIs with SNRIs 5

The American Gastroenterological Association recommends assessing pain relief after 3-4 weeks at each dose level before further titration, and using validated pain assessment tools such as the Brief Pain Inventory to track intensity and interference 1, 2
The European Crohn's and Colitis Organisation suggests referring patients to specialists if pain is refractory to optimized IBD therapy plus pregabalin at therapeutic doses, or if combination neuropathic analgesics are required 1, 2